PCRX Q3 2017 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q3 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$67M-1.5% YoY

Gross Profit

$49M72.9% margin

Operating Income

-$4M-5.3% margin

Net Income

-$8M-11.3% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-5.1%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$8M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$606M

Total Liabilities

$341M

Stockholders' Equity

$265M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$68M	-1.5%
Gross Profit	$49M	$25M	+94.8%
Operating Income	-$4M	-$21M	+82.9%
Net Income	-$8M	-$22M	+65.7%